Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

Saved in:
Bibliographic Details
Title: Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
Authors: Kelaidi, C.1, Beyne-Rauzy, O.1, Braun, T.1, Sapena, R.1, Cougoul, P.1, Adès, L.1, Pillard, F.1, Lamberto, C.1, Charniot, J.1, Guerci, A.1, Choufi, B.1, Stamatoullas, A.1, Slama, B.1, Renzis, B.1, Ame, S.1, Damaj, G.1, Boyer, F.1, Chaury, M.1, Legros, L.1, Cheze, S.1
Source: Annals of Hematology. May2013, Vol. 92 Issue 5, p633-633. 1p.
Database: Academic Search Ultimate
Description
ISSN:09395555
DOI:10.1007/s00277-013-1713-5